The momentum of biotech and biopharma companies is on the rise in anticipation of a new wave of emerging therapies moving through the industry’s development pipeline. In addition, the COVID-19 pandemic highlighted the importance of companies that can react quickly to circumstances and, in some cases, pivot their technology to meet immediate and changing therapeutic needs. New research into personalized medicines is giving rise to advanced technologies that speed R&D timelines and is also the industry’s understanding of biological and immunological processes.
